Merck Ends Revolution Medicines Talks As Oncology Plans And Valuation Weighed [Yahoo! Finance]
Revolution Medicines, Inc. (RVMD)
Company Research
Source: Yahoo! Finance
Merck paused acquisition discussions with Revolution Medicines after the two sides could not agree on valuation. The halted talks highlight a shift in Merck's approach to expanding its oncology presence as it reassesses potential deals. This development may influence how investors view both Merck's future transactions and broader pharma M&A activity. Merck, traded as NYSE:MRK, enters this chapter with its shares at $107.92 and a 1-year return of 14.9%. Over 5 years, the stock has returned 70.6%, with more muted moves in the shorter term, including a 1.4% return year to date. That backdrop provides context for how investors might interpret Merck's decision to walk away from these talks rather than stretch on price. For investors, the end of these discussions raises questions about where Merck may look next to support its oncology pipeline. The outcome could influence how the company allocates capital between internal research, partnerships, and potential future acquisitions, a
Show less
Read more
Impact Snapshot
Event Time:
RVMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RVMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RVMD alerts
High impacting Revolution Medicines, Inc. news events
Weekly update
A roundup of the hottest topics
RVMD
News
- Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective InhibitorGlobeNewswire
- Revolution Medicines (NASDAQ:RVMD) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..MarketBeat
- Tubulis Adds Steve Kelsey as Independent Director to its Advisory Board [Yahoo! Finance]Yahoo! Finance
- Revolution Medicines (RVMD) Dives 16.9% as Merck Withdraws Takeover Plan [Yahoo! Finance]Yahoo! Finance
- Merck Walks Away: What The Failed Acquisition Means For Revolution Medicines [Seeking Alpha]Seeking Alpha
RVMD
Earnings
- 11/5/25 - Miss
RVMD
Sec Filings
- 1/23/26 - Form 4
- 1/21/26 - Form 144
- 1/9/26 - Form 4
- RVMD's page on the SEC website